Matthew J. C. Ellis, M.B., B.Chir., Ph.D.

Book Chapters

• Suresh R, Ellis MJ
  Breast Cancer.
  In: The Washington Manual of Oncology, 2nd Edition (R. Govindan, ed), Lippincott Williams and Wilkins, pp 149-171, 2008
• Ellis MJ
  What have we gained from the application of biological "rationales"?
  ECCO 14 Educational Handbook, 2007
• Ellis MJ, Hayes, DF, Lippman ML
  Treatment of Metastatic Breast Cancer.
  In: Diseases of the Breast 3nd Edition, Eds Harris, J.R., Lippman, M.E., Morrow, M., Osborne, C.K. Lippincott Williams and Wilkins, 2004
• Ellis MJ
  Breast Cancer Gene Expression Analysis: The case for dynamic profiling.
  In: New Trends in Cancer for the 21st Century, Eds Llombart-Bosch, A. and Felipo, V. Kluwer Academic/Plenium Publishers, 2003
• Coope A, Ellis MJ
  The Genetics of Inherited Cancers.
  In: Oxford Textbook of Medicine, 4th Edition, p 229-237, Oxford University Press, 2003
• Coope A, Ellis MJ
  The Nature and Development of Cancer.
  In: Oxford Textbook of Medicine, 4th Edition, p 219-228, Oxford University Press, 2003
• Chiu S, Ellis MJ
  Endocrine Therapy for Advanced Breast Cancer.
  In: International Handbook of Breast Cancer. p 121-138. Ed. Johnson S. Euromed Publications 2002
• Ellis MJ
  Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist's Perspective.
  In: W. R. Miller and J. N. Ingle (eds.), Endocrine Therapy in Breast Cancer, pp. 181-195. New York: Marcel Dekker, 2002
• Ellis MJ, SwainS
  Steroid Hormone Therapies for Cancer.
  In: Cancer Chemotherapy and Biotherapy 3rd Edition. Eds Chabner, B.A. and Longo, D.L. Lippincott, Williams and Wilkins 2001
• Ellis MJ, Hayes DF, Lippman ML
  Treatment of Metastatic Breast Cancer.
  In: Diseases of the Breast 2nd Edition. Eds: Harris, J.R., Lippman, M.E., Morrow, M., Osborne, C.K. Lippincott Williams and Wilkins, 1999
• Ellis MJ
  The insulin-like growth factor network and breast cancer.
  In: Breast Cancer, Ed A Bowcock for "Contemporary Cancer Research" Humana Press: Totowa, New Jersey, 1999
• Ellis MJ, Garmrudi F, Cullen KJ
  Insulin Receptors (IGF1 and 2).
  In: The Encyclopedia of Cancer Volume 2, Editor in Chief, J.R. Bertino. Academic Press: San Diego, 1997
• Ellis MJ, Sikora K
  Molecular Biology of Cancer.
  In: Molecular Biology in Medicine, Eds. T.M. Cox and J. Sinclair. Blackwell Science Ltd, 1997
• Ellis MJ
  An Introduction to Transcription.
  In: The Molecular Biology of Cancer, Eds. Carney E., Sikora K. Wiley and Sons, 1990
• Ellis MJ, Sikora K
  Testicular Cancer.
  In: The Treatment of Cancer, Eds. Halnan K., Sikora K. Chapman & Hall, 1989

Books Edited

• Ellis MJ
  Aromatase Inhibitors for the Treatment of Breast Cancer. CMP HealthCare Media, Manhasset, New York, 2005

Published Scientific Reviews

• Fodora S, Ellis MJ
  The use of endocrine therapy in the treatment and prevention of breast cancer.
  ACPE Program number 356-000-04-029-H01, Pharmacy Education Novartis Pharmaceuticals Corp: 18:4 p1-32, 2004
• Ellis MJ
  Selective Aromatase Inhibitors: Current Indication and Future Perspectives.
  In: Diseases of the Breast Update, Series Editors, Marc E. Lippman and Jay Harris. Lippincott-Raven: Vol 2 Issue 1, 1998

Commentaries and Letters

• Ellis MJ
  Commentary on: Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer [J Clin Oncol 20:1467-1472, 2002].
  Breast Diseases: A Year Book Quarterly, 2003
• Ellis MJ
  Commentary on: Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer [Clin Cancer Res 20:1800-1808, 2002].
  Breast Diseases: A Year Book Quarterly, 2003
• Ellis MJ
  Commentary on: Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer [J Clin Oncol 20:1026-1035, 2002].
  Breast Diseases: A Year Book Quarterly 13:395, 2002
• Ellis MJ
  Commentary on: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma: results of two randomized trials designed for combined analysis [Cancer 92:2247-2258, 2001].
  Breast Diseases: A Year Book Quarterly 13:272-274, 2002
• Ellis MJ
  Commentary on: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex(tm) and tamoxifen alone or in combination' (ATAC) trial [Br J Cancer 85:317-324, 2001].
  Breast Diseases: A Year Book Quarterly 13:196, 2002
• Ellis MJ
  Commentary on: Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally
  advanced breast cancer [Clin Cancer Res 7:1230-1236, 2001].
  Breast Diseases: A Year Book Quarterly 12:455-456, 2002
• Ellis MJ
  Commentary on: Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years [J Natl Cancer Inst 93:456-462, 2001].
  Breast Diseases: A Year Book Quarterly 12:447-449, 2002

Editorials

• Ellis MJ
  Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board.
  J Natl Cancer Inst 2008 Feb 6;100(3):159-61
• Ellis MJ
  Current and future choices in endocrine therapy.
  Breast Cancer Research 2007;9(Suppl 2):S15
• Ellis MJ, Crowder R
  "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!
  Clin Cancer Res 2007 Oct 1;13(19):5661-2
• Naughton MJ, Ellis M
  "I'm pregnant and I have breast cancer".
  BMC Cancer 2007 May 30;7:93
• Ellis MJ
  Functional analysis of the breast cancer genome.
  J Clin Oncol. 2006 Apr 10;24(11):1649-50
• Crowder RJ, Ellis MJ
  Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.
  Breast Cancer Res. 2005;7(5):212-4
• Ellis MJ
  Neoadjuvant endocrine therapy for breast cancer: more questions than answers.
  J Clin Oncol 2005 Aug 1;23(22):4842-4
• Crowder RJ, Lombardi DP, Ellis MJ
  Successful targeting of ErbB2 receptors - is PTEN the key?
  Cancer Cell 2004 Aug;6(2):103-4
• Ellis M, Ballman K
  Trawling for genes that predict response to breast cancer adjuvant therapy.
  J Clin Oncol 2004 Jun 15;22(12):2267-9
• Ellis MJ, Hayes DF
  Refining breast cancer risk assessment with molecular markers: the next step?
  J Natl Cancer Inst 1999 Dec 15;91(24):2067-8